{"filing":{"accession_number":"0001140361-26-032028","cik":"0001281895","ticker":"RCKTW","company_name":"ROCKET PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"ef20079821_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/ef20079821_8k.htm"},"events":[{"id":26615,"run_id":24195,"accession_number":"0001140361-26-032028","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic Item 2.02 earnings release disclosing Rocket Pharmaceuticals' second quarter 2026 financial results for the period ended June 30, 2026. The filing includes detailed financial metrics (R\u0026D expenses of $29.5M, G\u0026A expenses of $17.4M, net income of $123.2M, cash position of $283.7M, and cash runway guidance into Q2 2028), along with operational highlights including FDA approval of KRESLADI, a $180M Priority Review Voucher sale, and clinical progress updates. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27803,"accession_number":"0001140361-26-032028","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 2.02 earnings release disclosing Rocket Pharmaceuticals' second quarter 2026 financial results for the period ended June 30, 2026. The filing includes detailed financial metrics (R\u0026D expenses of $29.5M, G\u0026A expenses of $17.4M, net income of $123.2M, cash position of $283.7M, and cash runway guidance into Q2 2028), along with operational highlights including FDA approval of KRESLADI, a $180M Priority Review Voucher sale, and clinical progress updates. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:22.765625+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27803,"accession_number":"0001140361-26-032028","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 2.02 earnings release disclosing Rocket Pharmaceuticals' second quarter 2026 financial results for the period ended June 30, 2026. The filing includes detailed financial metrics (R\u0026D expenses of $29.5M, G\u0026A expenses of $17.4M, net income of $123.2M, cash position of $283.7M, and cash runway guidance into Q2 2028), along with operational highlights including FDA approval of KRESLADI, a $180M Priority Review Voucher sale, and clinical progress updates. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:28:22.765625+00:00","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-08-10"}]}